medibic group (2369) Details

MediBIC Group, Co., Ltd. operates as a biotechnology company that specializes in pharmacogenomics (PGx). The company offers services for new drug development, including PGx project planning, sample collection arrangement, sample logistic, sample banking, DNA/RNA extraction and analysis, and data analysis for biomarker discovery of drug development. The company also offers development support products. Its product under development includes glufosfamide, a novel small molecule indicated for the treatment of various cancer types. In addition, the company provides personalized healthcare management support comprising Genetic Testing for Drug Response, a DNA screening test designed for individuals to find out if his/her genetics would affect excessive response to some drugs, which is marketed primarily through clinics and dispensing pharmacies; and a test designed for newborn babies to obstetricians. It primarily serves pharmaceutical companies, and research institutes and universities. The company was founded in 2000 and is headquartered in Tokyo, Japan.

medibic group (2369) Top Compensated Officers